FGFR2 and intrahepatic cholangiocarcinoma: It is estimated that 10%–30% of all solid tumors are dependent on the FGFR signaling, with 6%–15% of intrahepatic cholangiocarcinoma (ICC) harboring FGFR2 fusions and arrangements, and 20% of urothelial cancers driven by FGFR3-activating mutations or fusions.